UCB SA (UCBJY)
OTCMKTS · Delayed Price · Currency is USD
151.96
+1.25 (0.83%)
Mar 10, 2026, 3:52 PM EST
UCB SA Employees
UCB SA had 8,600 employees as of June 30, 2025.
Employees
8,600
Change
n/a
Growth
n/a
Revenue / Employee
$930,761
Profits / Employee
$187,331
Market Cap
58.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 8,600 | - | - | 8,600 | 0 |
| Dec 31, 2024 | 9,378 | 295 | 3.25% | 9,052 | 326 |
| Dec 31, 2023 | 9,083 | 380 | 4.37% | 8,450 | 633 |
| Dec 31, 2022 | 8,703 | 142 | 1.66% | 8,108 | 595 |
| Dec 31, 2021 | 8,561 | 190 | 2.27% | 8,006 | 555 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
UCB SA News
- 7 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 8 days ago - UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... - GuruFocus
- 8 days ago - Full Year 2025 Ucb SA Earnings Call Transcript - GuruFocus
- 8 days ago - Best Income Stocks to Buy for March 2nd - Nasdaq
- 20 days ago - Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight - GuruFocus
- 26 days ago - Best Income Stocks to Buy for February 12th - Nasdaq
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire